Dr. Pedro M. Barata
Claim this profileTulane University Health Sciences Center
Area of expertise
Kidney Cancer
Pedro M. Barata has run 10 trials for Kidney Cancer. Some of their research focus areas include:
Renal Cell Carcinoma
Pedro M. Barata has run 9 trials for Renal Cell Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
Tulane University Health Sciences Center
Hematology/Oncology Clinic PLLC
Clinical Trials Pedro M. Barata is currently running
Registry
for Advanced Prostate Cancer
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
Recruiting
1 award
N/A
5 criteria
Immunotherapy + Targeted Therapy
for Genitourinary Cancers
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting
1 award
Phase 2
21 criteria
More about Pedro M. Barata
Clinical Trial Related
1 year of experience running clinical trials · Led 20 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Pedro M. Barata has experience with
- Nivolumab
- Ipilimumab
- Cabozantinib
- Pembrolizumab
- Lenvatinib
- Prednisone
Breakdown of trials Pedro M. Barata has run
Kidney Cancer
Renal Cell Carcinoma
Prostate Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Pedro M. Barata specialize in?
Pedro M. Barata focuses on Kidney Cancer and Renal Cell Carcinoma. In particular, much of their work with Kidney Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Pedro M. Barata currently recruiting for clinical trials?
Yes, Pedro M. Barata is currently recruiting for 6 clinical trials in New Orleans Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Pedro M. Barata has studied deeply?
Yes, Pedro M. Barata has studied treatments such as Nivolumab, Ipilimumab, Cabozantinib.
What is the best way to schedule an appointment with Pedro M. Barata?
Apply for one of the trials that Pedro M. Barata is conducting.
What is the office address of Pedro M. Barata?
The office of Pedro M. Barata is located at: Tulane University Health Sciences Center, New Orleans, Louisiana 70112 United States. This is the address for their practice at the Tulane University Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.